1094 related articles for article (PubMed ID: 21518554)
1. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.
Lü TM; Yang SL; Wu WZ; Tan JM
Chin Med J (Engl); 2011 Mar; 124(5):664-8. PubMed ID: 21518554
[TBL] [Abstract][Full Text] [Related]
2. Preoperative single-bolus high-dose antithymocyte globulin as induction therapy in sensitized renal transplant recipients.
Wang D; Wu WZ; Yang SL; Chen JH; Tan JM
Chin Med J (Engl); 2006 Oct; 119(20):1683-8. PubMed ID: 17097014
[TBL] [Abstract][Full Text] [Related]
3. A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation.
Farney AC; Doares W; Rogers J; Singh R; Hartmann E; Hart L; Ashcraft E; Reeves-Daniels A; Gautreaux M; Iskandar SS; Moore P; Adams PL; Stratta RJ
Transplantation; 2009 Sep; 88(6):810-9. PubMed ID: 19920781
[TBL] [Abstract][Full Text] [Related]
4. Alemtuzumab induction and triple maintenance immunotherapy in kidney transplantation from donors after cardiac death.
Schadde E; D'Alessandro AM; Knechtle SJ; Odorico J; Becker Y; Pirsch J; Sollinger H; Fernandez LA
Transpl Int; 2008 Jul; 21(7):625-36. PubMed ID: 18397178
[TBL] [Abstract][Full Text] [Related]
5. One year results of preoperative single bolus ATG-Fresenius induction therapy in sensitized renal transplant recipients.
Wang D; Chen JH; Wu WZ; Yang SL; Wu GJ; Wang H; Tan JM
Transplant Proc; 2007; 39(1):69-72. PubMed ID: 17275476
[TBL] [Abstract][Full Text] [Related]
6. Pilot study of rapid steroid elimination with alemtuzumab induction therapy in kidney and pancreas transplantation.
Sundberg AK; Roskopf JA; Hartmann EL; Farney AC; Rohr MS; Stratta RJ
Transplant Proc; 2005 Mar; 37(2):1294-6. PubMed ID: 15848701
[TBL] [Abstract][Full Text] [Related]
7. Alemtuzumab with rapid steroid taper in simultaneous kidney and pancreas transplantation: comparison to induction with antithymocyte globulin.
Reddy KS; Devarapalli Y; Mazur M; Hamawi K; Chakkera H; Moss A; Mekeel K; Post D; Heilman R; Mulligan D
Transplant Proc; 2010; 42(6):2006-8. PubMed ID: 20692393
[TBL] [Abstract][Full Text] [Related]
8. Alemtuzumab induction in renal transplantation.
Hanaway MJ; Woodle ES; Mulgaonkar S; Peddi VR; Kaufman DB; First MR; Croy R; Holman J;
N Engl J Med; 2011 May; 364(20):1909-19. PubMed ID: 21591943
[TBL] [Abstract][Full Text] [Related]
9. Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation.
Thomas PG; Woodside KJ; Lappin JA; Vaidya S; Rajaraman S; Gugliuzza KK
Transplantation; 2007 Jun; 83(11):1509-12. PubMed ID: 17565326
[TBL] [Abstract][Full Text] [Related]
10. Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients.
Hill P; Cross NB; Barnett AN; Palmer SC; Webster AC
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD004759. PubMed ID: 28073178
[TBL] [Abstract][Full Text] [Related]
11. Rituximab induction therapy in highly sensitized kidney transplant recipients.
Yin H; Wan H; Hu XP; Li XB; Wang W; Liu H; Ren L; Zhang XD
Chin Med J (Engl); 2011 Jul; 124(13):1928-32. PubMed ID: 22088448
[TBL] [Abstract][Full Text] [Related]
12. Combination treatment of low dose Anti-Thymocyte Globulin (ATG), Rituximab and high dose Sirolimus as induction agents in immune-conditioned recipients.
Ravichandran P; Natrajan T; Jaganathan R
Int Immunopharmacol; 2006 Dec; 6(13-14):1973-6. PubMed ID: 17161350
[TBL] [Abstract][Full Text] [Related]
13. Alemtuzumab induction in deceased donor kidney transplantation.
Shin M; Song SH; Kim JM; Kwon CH; Joh JW; Lee SK; Kim SJ
Transplant Proc; 2011; 43(6):2365-78. PubMed ID: 21839271
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of induction therapy with alemtuzumab in kidney transplantation: a meta-analysis.
Shou ZF; Zhou Q; Cai JR; Cheng J; He Q; Wu JY; Chen JH
Chin Med J (Engl); 2009 Jul; 122(14):1692-8. PubMed ID: 19719973
[TBL] [Abstract][Full Text] [Related]
15. Comparison of single bolus ATG and Basiliximab as induction therapy in presensitized renal allograft recipients receiving tacrolimus-based immunosuppressive regimen.
Yang SL; Wang D; Wu WZ; Lin WH; Xu TZ; Cai JQ; Tan JM
Transpl Immunol; 2008 Jan; 18(3):281-5. PubMed ID: 18047938
[TBL] [Abstract][Full Text] [Related]
16. Alemtuzumab versus interleukin-2 receptor antibodies induction in living donor kidney transplantation.
Sampaio MS; Kadiyala A; Gill J; Bunnapradist S
Transplantation; 2009 Oct; 88(7):904-10. PubMed ID: 19935462
[TBL] [Abstract][Full Text] [Related]
17. Alemtuzumab induction in deceased donor kidney transplantation.
Huang E; Cho YW; Hayashi R; Bunnapradist S
Transplantation; 2007 Oct; 84(7):821-8. PubMed ID: 17984833
[TBL] [Abstract][Full Text] [Related]
18. The efficacy and safety of alemtuzumab and daclizumab versus antithymocyte globulin during organ transplantation: a meta-analysis.
Hao WJ; Zong HT; Cui YS; Zhang Y
Transplant Proc; 2012 Dec; 44(10):2955-60. PubMed ID: 23195005
[TBL] [Abstract][Full Text] [Related]
19. Campath-1H (alemtuzumab) as an induction agent for the prevention of graft rejection and preservation of renal function in kidney transplant patients: Philippine 3-year follow-up.
Muñoz AS; Cabanayan-Casasola CB; Danguilan RA; Padua FB; Ona ET
Transplant Proc; 2008 Sep; 40(7):2230-3. PubMed ID: 18790200
[TBL] [Abstract][Full Text] [Related]
20. Randomized trial of dual antibody induction therapy with steroid avoidance in renal transplantation.
Ciancio G; Gaynor JJ; Sageshima J; Guerra G; Zarak A; Roth D; Brown R; Kupin W; Chen L; Hanson L; Tueros L; Ruiz P; Livingstone AS; Burke GW
Transplantation; 2011 Dec; 92(12):1348-57. PubMed ID: 22027927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
